Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

No evidence for attenuated stress-induced extrastriatal dopamine signaling in psychotic disorder.

Hernaus D, Collip D, Kasanova Z, Winz O, Heinzel A, van Amelsvoort T, Shali SM, Booij J, Rong Y, Piel M, Pruessner J, Mottaghy FM, Myin-Germeys I.

Transl Psychiatry. 2015 Apr 14;5:e547. doi: 10.1038/tp.2015.37.

PMID:
25871972
2.

[Auto-immune disorders as a possible cause of neuropsychiatric syndromes].

Martinez-Martinez P, Molenaar PC, Losen M, Hoffmann C, Stevens J, de Witte LD, van Amelsvoort T, van Os J, Rutten BP.

Tijdschr Psychiatr. 2015;57(3):183-91. Dutch.

3.

Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome.

Vorstman JA, Breetvelt EJ, Duijff SN, Eliez S, Schneider M, Jalbrzikowski M, Armando M, Vicari S, Shashi V, Hooper SR, Chow EW, Fung WL, Butcher NJ, Young DA, McDonald-McGinn DM, Vogels A, van Amelsvoort T, Gothelf D, Weinberger R, Weizman A, Klaassen PW, Koops S, Kates WR, Antshel KM, Simon TJ, Ousley OY, Swillen A, Gur RE, Bearden CE, Kahn RS, Bassett AS; International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome.

JAMA Psychiatry. 2015 Apr 1;72(4):377-85. doi: 10.1001/jamapsychiatry.2014.2671.

4.

Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome.

Boot E, Butcher NJ, van Amelsvoort TA, Lang AE, Marras C, Pondal M, Andrade DM, Fung WL, Bassett AS.

Am J Med Genet A. 2015 Mar;167A(3):639-45. doi: 10.1002/ajmg.a.36928. Epub 2015 Feb 13.

PMID:
25684639
5.

123I-iododexetimide preferentially binds to the muscarinic receptor subtype M1 in vivo.

Bakker G, Vingerhoets WA, van Wieringen JP, de Bruin K, Eersels J, de Jong J, Chahid Y, Rutten BP, DuBois S, Watson M, Mogg AJ, Xiao H, Crabtree M, Collier DA, Felder CC, Barth VN, Broad LM, Bloemen OJ, van Amelsvoort TA, Booij J.

J Nucl Med. 2015 Feb;56(2):317-22. doi: 10.2967/jnumed.114.147488. Epub 2015 Jan 15.

PMID:
25593117
6.

Practical guidelines for managing adults with 22q11.2 deletion syndrome.

Fung WL, Butcher NJ, Costain G, Andrade DM, Boot E, Chow EW, Chung B, Cytrynbaum C, Faghfoury H, Fishman L, García-Miñaúr S, George S, Lang AE, Repetto G, Shugar A, Silversides C, Swillen A, van Amelsvoort T, McDonald-McGinn DM, Bassett AS.

Genet Med. 2015 Jan 8. doi: 10.1038/gim.2014.175. [Epub ahead of print] Review.

PMID:
25569435
7.

[Bridging the gap].

van Amelsvoort T.

Tijdschr Psychiatr. 2014;56(10):638-9. Dutch. No abstract available.

8.

[Reaction on 'Minocycline for schizophrenia: a brief overview'].

Evers R, van Amelsvoort T.

Tijdschr Psychiatr. 2014;56(8):561-2. Dutch. No abstract available.

9.

Serotonergic, noradrenergic and dopaminergic markers are related to cognitive function in adults with 22q11 deletion syndrome.

Evers LJ, Curfs LM, Bakker JA, Boot E, da Silva Alves F, Abeling N, Bierau J, Drukker M, van Amelsvoort TA.

Int J Neuropsychopharmacol. 2014 Aug;17(8):1159-65. doi: 10.1017/S1461145714000376. Epub 2014 Apr 8.

PMID:
24713114
10.

[Structural changes in DSM-5: the beginning of a transformation?].

van Amelsvoort TA, Van Den Eede F, Goethals K, van Marle HJ, Beekman AJ.

Tijdschr Psychiatr. 2014;56(3):152-6. Dutch.

11.

[DSM-5; a positive sound].

van Amelsvoort TA, Van Den Eede F, Goethals K, van Marle HJ, Beekman AJ.

Tijdschr Psychiatr. 2014;56(3):150-1. Dutch. No abstract available.

12.

Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome.

Schneider M, Debbané M, Bassett AS, Chow EW, Fung WL, van den Bree M, Owen M, Murphy KC, Niarchou M, Kates WR, Antshel KM, Fremont W, McDonald-McGinn DM, Gur RE, Zackai EH, Vorstman J, Duijff SN, Klaassen PW, Swillen A, Gothelf D, Green T, Weizman A, Van Amelsvoort T, Evers L, Boot E, Shashi V, Hooper SR, Bearden CE, Jalbrzikowski M, Armando M, Vicari S, Murphy DG, Ousley O, Campbell LE, Simon TJ, Eliez S; International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome.

Am J Psychiatry. 2014 Jun;171(6):627-39. Review.

13.

Psychopathology in adults with 22q11 deletion syndrome and moderate and severe intellectual disability.

Evers LJ, van Amelsvoort TA, Candel MJ, Boer H, Engelen JJ, Curfs LM.

J Intellect Disabil Res. 2014 Oct;58(10):915-25. doi: 10.1111/jir.12117. Epub 2014 Feb 17.

PMID:
24528781
14.

Pre-pulse inhibition and striatal dopamine in subjects at an ultra-high risk for psychosis.

De Koning MB, Bloemen OJ, Van Duin ED, Booij J, Abel KM, De Haan L, Linszen DH, Van Amelsvoort TA.

J Psychopharmacol. 2014 Feb 12;28(6):553-560. [Epub ahead of print]

PMID:
24526133
15.

Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What's the Evidence?

Vingerhoets WA, Bloemen OJ, Bakker G, van Amelsvoort TA.

Front Psychiatry. 2013 Dec 4;4:157. doi: 10.3389/fpsyt.2013.00157. Review.

16.

Dopaminergic modulation of the reward system in schizophrenia: a placebo-controlled dopamine depletion fMRI study.

da Silva Alves F, Bakker G, Schmitz N, Abeling N, Hasler G, van der Meer J, Nederveen A, de Haan L, Linszen D, van Amelsvoort T.

Eur Neuropsychopharmacol. 2013 Nov;23(11):1577-86. doi: 10.1016/j.euroneuro.2013.06.008. Epub 2013 Aug 24.

17.

Deep brain stimulation induces striatal dopamine release in obsessive-compulsive disorder.

Figee M, de Koning P, Klaassen S, Vulink N, Mantione M, van den Munckhof P, Schuurman R, van Wingen G, van Amelsvoort T, Booij J, Denys D.

Biol Psychiatry. 2014 Apr 15;75(8):647-52. doi: 10.1016/j.biopsych.2013.06.021. Epub 2013 Aug 12.

PMID:
23938318
18.

Metabolic alterations associated with schizophrenia: a critical evaluation of proton magnetic resonance spectroscopy studies.

Schwerk A, Alves FD, Pouwels PJ, van Amelsvoort T.

J Neurochem. 2014 Jan;128(1):1-87. doi: 10.1111/jnc.12398. Epub 2013 Sep 30. Review.

PMID:
23937509
19.

The detection of novelty relies on dopaminergic signaling: evidence from apomorphine's impact on the novelty N2.

Rangel-Gomez M, Hickey C, van Amelsvoort T, Bet P, Meeter M.

PLoS One. 2013 Jun 20;8(6):e66469. doi: 10.1371/journal.pone.0066469. Print 2013.

20.

Effects of cannabis use on event related potentials in subjects at ultra high risk for psychosis and healthy controls.

van Tricht MJ, Harmsen EC, Koelman JH, Bour LJ, van Amelsvoort TA, Linszen DH, de Haan L, Nieman DH.

Int J Psychophysiol. 2013 May;88(2):149-56. doi: 10.1016/j.ijpsycho.2013.03.012. Epub 2013 Mar 27.

PMID:
23541998
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk